Pathological complete response (pCR) after neoadjuvant chemotherapy is a strong prognostic marker at the patient level, being consistently associated with improved event-free and overall survival, particularly in biologically aggressive subtypes such as triple-negative and HER2-positive breast cancers [7,8]. Here, ERBB2 is linked to breast cancer.